Profile data is unavailable for this security.
About the company
Sensei Biotherapeutics, Inc. is a clinical-stage immuno-oncology company, which is focused on the discovery and development of therapeutics for cancer patients. Through its Tumor Microenvironment Activated biologics (TMAb) platform, the Company develops conditionally active therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment to unleash T cells against tumors. Its lead investigational candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation checkpoint selectively within the low pH tumor microenvironment. It is also developing SNS-102, a conditionally active monoclonal antibody targeting V-Set and Immunoglobulin Domain Containing 4 (VSIG-4); SNS-103, a conditionally active monoclonal antibody targeting ecto-nucleoside triphosphate diphosphohydrolase-1 (ENTPDase1), CD39; and SNS-201, a conditionally active VISTAxCD28 bispecific antibody.
- Revenue in USD (TTM)0.00
- Net income in USD-31.92m
- Incorporated2017
- Employees27.00
- LocationSensei Biotherapeutics Inc1405 Research Blvd, Suite 125ROCKVILLE 20850United StatesUSA
- Phone+1 (240) 243-8000
- Fax+1 (302) 531-3150
- Websitehttps://www.senseibio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Inhibitor Therapeutics Inc | 0.00 | -3.17m | 18.58m | 3.00 | -- | 4.00 | -- | -- | -0.0184 | -0.0184 | 0.00 | 0.0269 | 0.00 | -- | -- | 0.00 | -34.05 | 27.48 | -34.48 | 32.70 | -- | -- | -- | -- | -- | -- | 0.00 | 0.00 | -- | -- | -125.39 | -- | -- | -- |
| VBI Vaccines Inc | 9.41m | -83.99m | 18.61m | 131.00 | -- | -- | -- | 1.98 | -6.93 | -6.93 | 0.4818 | -0.2166 | 0.0923 | 1.40 | 37.05 | 71,839.70 | -81.40 | -46.58 | -171.57 | -58.62 | -24.06 | -277.46 | -881.79 | -2,755.98 | 0.2116 | -1.60 | 1.13 | -- | 702.40 | 20.94 | 17.18 | -- | -32.07 | -- |
| Synlogic Inc | 3.21m | -73.22m | 18.73m | 6.00 | -- | 1.40 | -- | 5.84 | -10.62 | -10.62 | 0.4576 | 1.15 | 0.0495 | -- | -- | 534,166.70 | -113.09 | -40.57 | -134.57 | -43.82 | -- | -- | -2,284.68 | -3,245.93 | -- | -- | 0.00008 | -- | 185.68 | 5.99 | 13.40 | -- | -48.05 | -- |
| Ibio Inc | 50.00k | -17.13m | 18.89m | 26.00 | -- | 0.7502 | -- | 377.72 | -13.10 | -17.09 | 0.0262 | 2.92 | 0.0011 | -- | 0.0065 | 1,923.08 | -36.24 | -28.09 | -67.39 | -32.63 | -- | -- | -34,258.00 | -1,467.30 | -- | -- | 0.3666 | -- | -100.00 | -- | 0.9764 | -- | 42.90 | -- |
| AIM ImmunoTech Inc | 193.00k | -31.12m | 19.74m | 26.00 | -- | 4.68 | -- | 102.30 | -0.637 | -0.637 | 0.004 | 0.096 | 0.0072 | -- | 0.2189 | 7,423.08 | -116.00 | -45.64 | -148.40 | -48.35 | 74.09 | -231.75 | -16,123.32 | -11,695.01 | -- | -- | 0.3478 | -- | 43.26 | -11.26 | -48.94 | -- | 35.73 | -- |
| Sensei Biotherapeutics Inc | 0.00 | -31.92m | 19.81m | 27.00 | -- | 0.3388 | -- | -- | -1.20 | -1.20 | 0.00 | 2.33 | 0.00 | -- | -- | 0.00 | -36.55 | -47.03 | -39.39 | -54.33 | -- | -- | -- | -- | -- | -- | 0.0241 | -- | -- | -- | 29.82 | -- | 42.16 | -- |
| Lyra Therapeutics Inc | 1.68m | -68.88m | 19.84m | 109.00 | -- | 0.256 | -- | 11.81 | -1.23 | -1.23 | 0.0297 | 1.27 | 0.0143 | -- | -- | 19,090.91 | -58.52 | -58.01 | -68.02 | -68.69 | -- | -- | -4,099.82 | -6,235.31 | -- | -- | 0.00 | -- | 14.31 | 4.60 | -13.39 | -- | 95.14 | -- |
| Lumos Pharma Inc | 1.53m | -37.13m | 19.89m | 33.00 | -- | 1.14 | -- | 13.04 | -4.59 | -4.59 | 0.1886 | 2.15 | 0.0332 | -- | 8.01 | 46,212.12 | -80.89 | -29.78 | -90.15 | -32.32 | -- | -- | -2,434.69 | -2,937.61 | -- | -- | 0.00 | -- | 34.67 | -30.31 | -9.57 | -- | -- | -- |
| Indaptus Therapeutics Inc | 0.00 | -14.98m | 19.98m | 7.00 | -- | 2.13 | -- | -- | -1.78 | -1.78 | 0.00 | 1.10 | 0.00 | -- | -- | 0.00 | -87.86 | -66.55 | -97.46 | -81.23 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.68 | -- | -- | -- |
| Vincerx Pharma Inc | 0.00 | -38.25m | 20.20m | 42.00 | -- | -- | -- | -- | -1.79 | -1.79 | 0.00 | -0.029 | 0.00 | -- | -- | 0.00 | -130.68 | -- | -205.70 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 36.24 | -- | -- | -- |
| Neurosense Therapeutics Ltd | 0.00 | -11.28m | 20.23m | 16.00 | -- | -- | -- | -- | -0.7625 | -0.7625 | 0.00 | -0.1219 | 0.00 | -- | -- | 0.00 | -207.24 | -- | -395.72 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 8.59 | -- | -- | -- |
| Neurobo Pharmaceuticals Inc | 0.00 | -16.58m | 20.26m | 8.00 | -- | 2.01 | -- | -- | -3.26 | -3.26 | 0.00 | 2.05 | 0.00 | -- | -- | 0.00 | -68.36 | -95.57 | -108.01 | -135.64 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 10.72 | -- | 75.54 | -- |
| Eom Pharmaceutical Holdings Inc | 0.00 | -4.93m | 20.28m | 3.00 | -- | -- | -- | -- | -0.0435 | -0.0435 | 0.00 | -0.0212 | -- | -- | -- | 0.00 | -- | -126.34 | -- | -171.37 | -- | -- | -- | -- | -- | -- | 7.41 | -- | -- | -- | -254.37 | -- | -- | -- |
| MEI Pharma Inc | 66.75m | 26.16m | 20.65m | 46.00 | 0.7897 | 0.4048 | 0.7791 | 0.3094 | 3.93 | 3.93 | 10.02 | 7.66 | 0.6498 | -- | 29.15 | 1,451,174.00 | 25.46 | -25.31 | 30.38 | -28.59 | -- | -- | 39.18 | -122.05 | -- | -- | 0.00 | -- | 19.95 | 97.56 | 41.53 | -- | -- | -- |
| Evaxion Biotech A/S - ADR | 73.00k | -22.13m | 21.07m | 49.00 | -- | -- | -- | 288.61 | -81.29 | -81.29 | 0.2665 | -1.25 | 0.0042 | -- | 0.091 | 1,489.80 | -126.74 | -100.11 | -183.85 | -131.65 | -- | -- | -30,308.22 | -131,560.30 | -- | -30.92 | 1.77 | -- | -- | -- | 4.51 | -- | 65.53 | -- |
| America Great Health | 219.13k | -859.20k | 21.11m | 7.00 | -- | -- | -- | 96.35 | -0.00004 | -0.00004 | 0.00001 | -0.0002 | 0.6746 | 0.0721 | 18.16 | 31,304.29 | -265.62 | -543.96 | -- | -- | 95.92 | -247.36 | -393.74 | -1,193.55 | 0.035 | -1.37 | -- | -- | 95.23 | -- | 84.35 | -- | -- | -- |
Data as of May 24 2024. Currency figures normalised to Sensei Biotherapeutics Inc's reporting currency: US Dollar USD
9.01%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Newtyn Management LLCas of 31 Mar 2024 | 930.23k | 3.71% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 573.84k | 2.29% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 211.00k | 0.84% |
| Geode Capital Management LLCas of 31 Mar 2024 | 136.32k | 0.54% |
| NFS Netfonds Financial Service GmbHas of 30 Sep 2023 | 113.96k | 0.46% |
| Bridgeway Capital Management LLCas of 31 Mar 2024 | 112.90k | 0.45% |
| Bank of America, NA (Private Banking)as of 31 Mar 2024 | 90.76k | 0.36% |
| Millennium Management LLCas of 31 Mar 2024 | 32.59k | 0.13% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 31.31k | 0.13% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 26.05k | 0.10% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
